Can Standard Health Technology Assessment Approaches Help Guide the Price of Orphan Drugs in Canada? A Review of Submissions to the Canadian Agency for Drugs and Technologies in Health Common Drug Review

Orphan drugs have high acquisition costs and when standard health technology assessment (HTA) approaches are used to assess their cost-effectiveness, they often appear not cost-effective. The Canadian Patented Medicine Review Board (PMPRB), through new regulations, will apply HTA assessment results...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clinicoecon Outcomes Res
Auteurs principaux: Balijepalli, Chakrapani, Gullapalli, Lakshmi, Druyts, Eric, Yan, Kevin, Desai, Kamal, Barakat, Stephane, Locklin, Jason
Format: Artigo
Langue:Inglês
Publié: Dove 2020
Sujets:
Review
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7455764/
https://ncbi.nlm.nih.gov/pubmed/32922050
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S264589
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires